FY2025 Earnings Forecast for NKTR Issued By Zacks Research

Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at Zacks Research issued their FY2025 EPS estimates for Nektar Therapeutics in a research report issued on Monday, June 30th. Zacks Research analyst K. Das forecasts that the biopharmaceutical company will post earnings of ($8.76) per share for the year. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share.

Several other equities research analysts also recently weighed in on the stock. Oppenheimer upgraded shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $90.00 target price for the company in a research note on Friday, March 14th. Wall Street Zen downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 14th. Jefferies Financial Group raised Nektar Therapeutics from a “hold” rating to a “buy” rating and upped their price objective for the company from $15.00 to $30.00 in a research note on Friday, April 11th. HC Wainwright increased their price objective on Nektar Therapeutics to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, June 24th. Finally, William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $84.17.

Nektar Therapeutics Stock Performance

Shares of Nektar Therapeutics stock opened at $24.65 on Thursday. The company has a market capitalization of $305.91 million, a P/E ratio of -2.57 and a beta of 0.94. Nektar Therapeutics has a 1 year low of $6.48 and a 1 year high of $37.38. The company’s fifty day moving average is $12.71 and its two-hundred day moving average is $12.49.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing analysts’ consensus estimates of ($2.70) by ($0.60). Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. The business had revenue of $10.46 million during the quarter, compared to analyst estimates of $15.61 million. During the same period in the previous year, the firm earned ($2.70) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NKTR. Squarepoint Ops LLC acquired a new position in Nektar Therapeutics during the fourth quarter worth $130,000. Wellington Management Group LLP boosted its position in shares of Nektar Therapeutics by 10.4% during the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 49,319 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its position in shares of Nektar Therapeutics by 267.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 175,193 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 127,459 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Nektar Therapeutics by 23.3% during the 1st quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 41,948 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in shares of Nektar Therapeutics by 32.8% in the 4th quarter. Ameriprise Financial Inc. now owns 373,948 shares of the biopharmaceutical company’s stock valued at $348,000 after purchasing an additional 92,346 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.